Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
Barth DA, Moik F, Steinlechner S, Posch F, Mayer MC, Sandner AM, Berton F, Schlintl V, Koch L, John N, Wurm R, Pichler M, Bauernhofer T, Reimann P, Wohlkönig C, Richtig E, Winder T, Preusser M, Jost PJ, Ay C, Gerger A, Terbuch A, Riedl JM. Barth DA, et al. Among authors: richtig e. J Immunother Cancer. 2023 Dec 14;11(12):e007765. doi: 10.1136/jitc-2023-007765. J Immunother Cancer. 2023. PMID: 38097343 Free PMC article.
Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing-A Prospective Feasibility Study.
Berger M, Thueringer A, Franz D, Dandachi N, Talakić E, Richtig G, Richtig E, Rohrer PM, Koch L, Wolf IH, Koch C, Rainer BM, Koeller M, Pichler M, Gerritsmann H, Kashofer K, Aigelsreiter A. Berger M, et al. Among authors: richtig e, richtig g. Cancers (Basel). 2021 Jun 21;13(12):3101. doi: 10.3390/cancers13123101. Cancers (Basel). 2021. PMID: 34205831 Free PMC article.
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler JM, Karasek M, Koch L, Silmbrod R, Mangana J, Latifyan S, Aedo-Lopez V, Kehrer H, Weihsengruber F, Koelblinger P, Posch C, Kofler J, Michielin O, Richtig E, Hafner C, Hoeller C. Ressler JM, et al. Among authors: richtig e. J Immunother Cancer. 2021 Feb;9(2):e001701. doi: 10.1136/jitc-2020-001701. J Immunother Cancer. 2021. PMID: 33608376 Free PMC article.
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB, Lenders MM, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer SH, Kimeswenger S, Oellinger A, Forschner A, Leiter U, Weide B, Gassenmaier M, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen VA, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Eigentler TK. Wagner NB, et al. Among authors: richtig e, richtig g. J Immunother Cancer. 2021 May;9(5):e002350. doi: 10.1136/jitc-2021-002350. J Immunother Cancer. 2021. PMID: 33986126 Free PMC article.
Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types.
Robinson I, Hochmair MJ, Schmidinger M, Absenger G, Pichler M, Nguyen VA, Richtig E, Rainer BM, Ay L, Jansen C, Pacífico C, Knabl A, Sladek B, Gasche N, Valipour A. Robinson I, et al. Among authors: richtig e. Cancers (Basel). 2023 Jun 21;15(13):3268. doi: 10.3390/cancers15133268. Cancers (Basel). 2023. PMID: 37444378 Free PMC article.
140 results